The purpose of this study was to investigate whether inhaled frusemide was able to inhibit the increase in nonspecific bronchial reactivity that occurs after the early response to allergen exposure in subjects with allergic rhinitis or asthma (or both Frusemide, a drug widely used for its natriuretic properties, has been shown, when given by inhalation, to provide substantial protection against bronchoconstriction induced by various stimuli,56 including allergen exposure in sensitised individuals.78
preceded by inhaled frusemide (40 mg frusemide in 4 ml buffered saline) or placebo (4 ml of diluent solution), according to a randomised, double blind, crossover design. All allergen studies were separated by at least seven days. A methacholine challenge was performed two hours after the allergen challenge, a time when the early response to allergen had completely resolved. Frusemide inhibited the early response to antigen, causing mean (95% confidence interval) protection of 87 6% (96-80%) for the maximum fall in FEV,. The increase in non-specific airway reactivity that occurred after antigen when this was preceded by placebo was reduced by frusemide. The mean (95% CI) difference in PD,l values between the placebo and the frusemide days was 173 (2-30- 1 16 ) doubling doses of methacholine. These results confirm that frusemide is highly effective in preventing the early response to allergen, and show that it inhibits the increase in reactivity to methacholine that follows the early response.
A single exposure to antigen, as in an antigen challenge test, is capable of inducing an increase in non-allergic bronchial responsiveness.' This phenomenon was thought to be related to the late response to antigen,2 though recent studies have shown that nonspecific reactivity increases soon after the early response and some hours before the onset of the late response.3 4 Frusemide, a drug widely used for its natriuretic properties, has been shown, when given by inhalation, to provide substantial protection against bronchoconstriction induced by various stimuli,56 including allergen exposure in sensitised individuals.78
In subjects with allergic asthma and early and late asthmatic responses to inhaled allergen frusemide, inhaled before the allergen challenge, reduced the early and late response to antigen but did not protect against the increased airway reactivity to methacholine seen 24-30 hours after inhalation of antigen.7 Our study was designed to investigate whether frusemide, in addition to suppressing the early response to antigen, prevents the increase in airway responsiveness to methacholine that. occurs two hours after the antigen challenge.
Methods

SUBJECTS
Ten patients (eight men and two women, aged 14-40 years) participated in the study after giving informed consent. All had a previous diagnosis (based on symptoms and previous treatment) of allergic rhinitis or asthma, or both, positive immediate antigen skin test responses (Alpha test, Dome/Hollister-Stier, Bayropharm Italiana, Milan), a serum concentration of total IgE of 200 IU or more (immunofluorimetric method, IgE FAST-Plus, 3M Baxter, Trieste), and positive results in immunoenzymatic serological tests for specific IgE antibodies (Phadezyme, Pharmacia Diagnostics, Milan) against Dermatophagoides pteronyssinus (eight patients) or grass pollen (two patients). All subjects had normal pulmonary function on admission (FEV, 80% of predicted or above), had no current symptoms, and had taken no medicine for at least four weeks before the study. All had an early response to antigen challenge (AFEV, > 15%). PROVOCATION Verdiani, Di Carlo, Baronti, Bianco centrations of 0.406 and 40/O in buffered saline. Two 2 ml vials of frusemide 10 mg/ml (Lasix, approved for intravenous administration) or placebo (a diluent solution consisting of sodium chloride 28 0 mg, sodium hydroxyl to reach pH 9, and water to make up 4 ml) matched for osmolarity (295 mmol/kg), which was kindly provided by Hoechst Italia Sud, L'Aquila, were used for aerosol delivery.
Methacholine aerosol was generated by a de Vilbiss nebuliser attached to a dose metering device (breath activated solenoid valve, timing circuit, and compressed air source) and delivered for 0 6 second during slow, deep inspirations from functional residual capacity to total lung capacity. With this method the mean volume output of the nebuliser was 0 01 (SD 0 001) ml per breath. Aerosols of allergen, frusemide, and placebo were delivered via a jet nebuliser (Nebula, Markos, Monza, Italy), 4 ml aliquots of allergen solution, frusemide, and placebo being used. During the 20 minutes when patients inhaled frusemide or placebo from the nebuliser the mean weight of frusemide delivered to the mouth (calculated on five occasions by differential weighing after placing 4 ml frusemide solution in the reservoir) was 28-3 (SEM 0 6) mg. The same nebuliser was always used for all tests in an individual patient. A bronchial provocation test with methacholine was performed according to the recommendations of the working group of the Societa Italiana per la Patofisiologia Respiratoria.9 FEV, was measured after patients had inhaled three doses of buffered saline solution. Subjects then inhaled increasing doses of methacholine, ranging from 40 to 4000 ,ug, and FEV, was measured two minutes after each dose. The procedure was stopped when the FEV, fell by 1500 from the postsaline FEVI. Dose hours after the end of the allergen inhalation.
If the FEV, was above 950% of the baseline value, the patient underwent a methacholine provocation test. The timing of the initial methacholine challenge was arranged so that all three methacholine challenges were performed at the same time on each day. At the end of each study day subjects were questioned about side effects. They were also asked specifically about development of cough, wheezing, or breathlessness six to eight hours after the allergen challenge and during the night and following days.
STATISTICAL ANALYSIS
The protective effect of frusemide on the early response to antigen was calculated as a percentage for each patient according to the formula (placebo -frusemide)/placebo x 100, on the basis either of the area under the time-response curve of the change from baseline (AUC) or of the maximum fall in FEVy five to 20 minutes after challenge expressed as percentage of the value at time zero. Methacholine PD15 values were logarithmically transformed to stabilise group variance before analysis. The change between placebo and frusemide values of methacholine PD15 was calculated in terms of doubling doses for each subject.
Comparison of multiple groups was performed by the use of two way analysis of variance combined with the least significant difference method.'0 The Paired Student's t test was used to compare differences between two groups. A p value of 0 05 or less for two tailed comparison was considered significant. Unless stated otherwise data are expressed as means and 950o confidence intervals (CI).
Results
Baseline FEVy on the two study days was similar to the values recorded during the preliminary challenge test. There were no significant differences in FEVy values before and after placebo and frusemide treatment on the two study days (table 1) .
RESPONSE TO ANTIGEN
After treatment with placebo all the patients had an early response to the antigen challenge, with a maximum fall in FEV1 from baseline of 173%o (950°o CI 12 5-22 10O); this was significant five, 10, 15 and 20 minutes after challenge (figure).
After treatment with inhaled frusemide the airway response to allergen was substantially Two hours after antigen challenge recovery was complete on both study days, and there were no differences in FEV, on the frusemide and placebo days before the methacholine challenge.
There was wide intersubject variability in the bronchial response to methacholine in the preliminary test (table 2) . All patients showed a substantial increase in bronchial reactivity to methacholine two hours after antigen exposure when this was preceded by placebo. The increase was inhibited by frusemide. The mean difference in PD,5 values between placebo and frusemide was 1-73 (2-30-1 16) doubling doses of methacholine. The degree of protection was not affected by the order of treatments.
Five subjects reported cough and shortness of breath several hours after the initial antigen challenge. The same delayed symptoms followed the antigen challenge after placebo; they were prevented by frusemide pretreatment.
No subject experienced any side effect after inhaled frusemide; in particular, none reported any increase in diuresis.
Discussion
In our atopic patients frusemide, administered by aerosol, provided strong protection against antigen induced bronchoconstriction. This confirms the results of previous studies, carried out under similar experimental conditions.78 The results of the trials differ only quantitatively, in that in the current study frusemide caused almost complete protection against antigen challenge, whereas in the former studies it caused substantial attenuation, but did not suppress the airway response to allergen completely. This may be because we i14 - In a previous study7 frusemide, inhaled as a single dose before the antigen challenge, attenuated both the early and the late components of the dual asthmatic response but did not alter the airway response to methacholine measured 24-30 hours after antigen exposure. In our study frusemide completely blunted the early increase in non-specific reactivity. In our previous study7 the protection afforded by frusemide against the late bronchoconstrictor response to antigen was slightly less than the protection against the early response. Repeated inhalations of frusemide during an antigen Verdiani, Di Carlo, Baronti, Bianco study may differ from a single dose before antigen challenge in its effect both on the late response to antigen and on non-specific reactivity assessed 24 hours after allergen exposure.
The active ion transport that occurs at the level of surface cells, accounts for the electrical characteristics of airway epithelium."2 We may reasonably suggest that frusemide, by inhibiting ion transport across tracheobronchial epithelial cells, can modify transmucosal electrochemical gradients. Inhibition of chloride secretion by frusemide has been found in vitro in canine tracheal epithelium'3 and in cultured tracheal epithelial cells.'4 If similar changes occur in man in vivo, they might modify the function ofairway epithelium, and hence lessen the airway response to stimuli such as inhaled allergen.
Mechanisms other than modification of the ionic environment of the epithelium should also be considered. Inhibition of the early response by frusemide raises the possibility that inhibition of mediator release might be important. The osmolarity ofairway periciliary fluid may affect the function of effector cells, such as mast cells, which play an undoubted part in the pathogenesis of allergic airway disorders.'5 Activation of pulmonary mast cells has been shown in atopic, asthmatic, and nonasthmatic subjects after bronchoalveolar challenge,'6 and hyperosmotic stimuli have been shown to be capable of both inducing mediator release by mast cells and enhancing their activation in response to allergen exposure. 7 18 The possibility that frusemide is indirectly affecting inflammatory cell function by influencing ion and water movements across the airway epithelium cannot therefore be excluded.
In conclusion, our study confirms that frusemide provides strong protection against allergen induced bronchoconstriction in atopic patients. It also inhibits the enhancement of non-allergic bronchial reactivity that occurs shortly after resolution of the early response.
